Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Japanese patients with advanced solid tumors for which suitable effective standard treatment does not exist or is no longer effective

• Relatively good overall health other than cancer

Exclusion Criteria:

• Poor bone marrow function (not producing enough blood cells)

• Poor liver or kidney function

• Serious concomitant illness